KBC Group
JANX icon

KBC Group’s Janux Therapeutics JANX Stock Holding History

KBC Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19K Hold
1,387
– – ﹤0.01% 1842
2025
Q4 		$19K Hold
1,387
– – ﹤0.01% 1726
2025
Q3 		$34K Hold
1,387
– – ﹤0.01% 1714
2025
Q2 		$32K Sell
1,387
-1,074
-44% -$28.3K ﹤0.01% 1695
2025
Q1 		$66K Buy
+2,461
New +$92.8K ﹤0.01% 1704

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KBC Group's JANX Position: Q1 2026 in Review

KBC Group held its Janux Therapeutics (JANX) position steady in Q1 2026 at 1,387 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #1842.

KBC Group first reported a position in JANX in Q1 2025 and has held it in 5 quarters since. The position peaked at $66K in Q1 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • KBC Group held 1,387 shares of Janux Therapeutics worth $19K as of Q1 2026.
  • KBC Group left its Janux Therapeutics share count unchanged in Q1 2026.
  • Janux Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1842 holding.
  • KBC Group first reported a position in Janux Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • KBC Group's Janux Therapeutics position peaked at $66K in Q1 2025.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.